Owlet, the maker of the first FDA-cleared over-the-counter wearable infant monitor, has been shifting from a hardware-focused business toward a pediatric health platform centered on recurring subscription revenue. This earnings release stood out because it showed whether the company could maintain its growth trajectory while handling the initial full quarter of elevated import tariffs. The fourth quarter also included the important holiday sales window, offering a clear read on demand for products like the Dream Sock, Dream Duo, and the new DreamSight camera. With the company achieving adjusted EBITDA profitability for the first full year, I was watching closely to see signs that the model can scale profitably into 2026.
Owlet reported fourth quarter 2025 revenue of $26.6 million, a 29.6% increase over the prior-year period, bringing full-year 2025 revenue to $105.7 million, up 35.4% year over year. The fourth-quarter figure came in modestly ahead of the roughly $26.0 million consensus estimate. On the bottom line, GAAP results fell short of expectations, with a reported net loss per share of $0.39 versus a consensus loss of roughly $0.14, reflecting non-cash items including warrant liability adjustments. I also checked this using Tickeron’s AI Screener to compare the stock against peers in the sector.
Fourth quarter gross margin was 47.6%, pressured by higher tariff costs, while full-year gross margin reached a record 50.6%. Fourth quarter adjusted EBITDA was $0.1 million, down from $0.5 million a year earlier, while full-year adjusted EBITDA was a record $2.0 million, a $3.8 million improvement over 2024. Management noted that tariffs reduced full-year gross margin by 270 basis points.
Heading into the release, sentiment reflected optimism around Owlet's momentum but caution over tariff exposure. The company's record full-year revenue and gross margin provided a positive backdrop, while fourth-quarter adjusted EBITDA of just $0.1 million—well below the prior year—highlighted how tariff costs are compressing near-term profitability. The initiation of 2026 guidance with a projected rebound in adjusted EBITDA signaled management's confidence that top-line growth and subscription scaling can offset import cost pressures. Investors weighed the record results against the softer fourth-quarter margin and the modestly lower-than-expected GAAP EPS figure, keeping attention on whether the 2026 ramp materializes as guided.
Owlet's 2026 guidance is the central reference point for the quarters ahead. For the first quarter of 2026, the company expects revenue of $20 million to $21 million, gross margins of 50% to 52%, and adjusted EBITDA of negative $2.5 million to negative $1.5 million. For the full year, it projects revenue of $126 million to $130 million, representing 19% to 23% growth, with gross margins of 49% to 52% including tariff costs and adjusted EBITDA of $3 million to $5 million.
Several factors will shape whether the company meets these targets. Tariff policy remains the most visible near-term risk, since import costs directly pressure gross margin. Investors should also track the growth of the Owlet 360 subscription base, which surpassed 110,000 paying subscribers and is now expanding into international markets. A planned commercial launch in India in 2026, following regulatory clearance, represents a meaningful new revenue opportunity.
Finally, the healthcare channel is an emerging growth vector worth monitoring. Owlet's partnership with the Children's Hospital of the King's Daughters and its remote patient monitoring integration point toward a larger, insurance-reimbursed market for its medical-grade BabySat device. Progress on hospital partnerships, subscription attach rates, and margin recovery in the face of tariffs will be the key signals to watch in upcoming quarters.
In my ongoing research, Tickeron’s AI Screener has become a useful resource for quickly filtering comparable names in consumer health and technology sectors. It allows me to apply custom criteria around fundamentals, patterns, and performance to surface ideas that might otherwise take hours to identify manually. This kind of tool helps keep my process efficient when evaluating companies like Owlet alongside peers.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where OWLT declined for three days, in 298 of 329 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 52 cases where OWLT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 87%.
OWLT broke above its upper Bollinger Band on November 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for OWLT entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where OWLT's RSI Indicator exited the oversold zone, 24 of 27 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 89%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on OWLT as a result. In 68 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for OWLT just turned positive on November 02, 2026. Looking at past instances where OWLT's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.
Following a +4.14% 3-day Advance, the price is estimated to grow further. Considering data from situations where OWLT advanced for three days, in 210 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.847) is normal, around the industry mean (4.142). P/E Ratio (-13.900) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.967) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 75 (best 1 - 100 worst), indicating slightly worse than average price growth. OWLT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OWLT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalNursingServices